Adaptive Biotechnologies vs Heartflow

Adaptive Biotechnologies (ADPT), health care, and Heartflow (HTFL), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Adaptive Biotechnologies is worth $4.6B on the stock market and Heartflow $4.1B: Adaptive Biotechnologies is valued at 11% more. Adaptive Biotechnologies's operating margin in its latest fiscal year was -20.6% and Heartflow's -36.4%. Over the past year Adaptive Biotechnologies's share price has moved +103% and Heartflow's +71.6%.

Key facts

Adaptive Biotechnologies market value
$4.6B
Heartflow market value
$4.1B
Heartflow P/E
70.3
Adaptive Biotechnologies revenue
$277MFY to 2025-12-31
Heartflow revenue
$176MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Adaptive Biotechnologies vs Heartflow: every measure side by side
Measure Adaptive Biotechnologies Heartflow
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$4.6Bhigher$4.1Blower
Revenue$277Mhigher$176Mlower
Earnings-$59.5Mhigher-$116.8Mlower
Employees624lower843higher
Total assets$512.7Mhigher$359.5Mlower
Valuation
P/E—70.3
P/S16.7lower23.5higher
P/B26.1higher14.6lower
Dividend yield0.00%0.00%
Profitability
Operating margin-20.6%higher-36.4%lower
Balance sheet
Net assets$218.8Mlower$300.6Mhigher
Total liabilities$287.7Mhigher$58.8Mlower
Total debt$131.2M—
Cash on hand$70.5Mhigher$44.8Mlower
Price change
Today+2.22%higher+0.45%lower
1 year+103%higher+71.6%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Adaptive Biotechnologies only (2)

Heartflow only (2)

Percentages are each holding's share of that investor's reported portfolio (under "Both": Adaptive Biotechnologies / Heartflow). Who owns ADPT · Who owns HTFL

Further comparisons

Learn

Questions and answers

Which is bigger, Adaptive Biotechnologies or Heartflow?

By market value, Adaptive Biotechnologies is the larger: $4.6B against $4.1B for Heartflow. By revenue in its latest fiscal year, Adaptive Biotechnologies is the larger: $277M against $176M for Heartflow.

Which has the higher operating margin?

Adaptive Biotechnologies: -20.6%, against -36.4% for Heartflow. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Adaptive Biotechnologies and Heartflow?

In their latest 13F filings, Polen Capital team holds both.

Cite this page

Funkfolio, “Adaptive Biotechnologies vs Heartflow”, data as of 18 November 2026. https://funkfolio.com/compare/adpt-vs-htfl

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.